!!Aija Linē - Selected publications
\\
1. Zandberga E, Kozirovskis V, Ābols A, Andrejeva D, Purkalne G and Linē A. Cell-free microRNAs as diagnostic, prognostic and predictive biomarkers in lung cancer. Genes, Chromosomes & Cancer. 2012 (accepted) (IF 3.3)\\
\\
2. Zayakin P, Ancāns G, Siliņa K, Meistere I, Kalniņa Z, Andrejeva D, Endzeliņš E, Ivanova L, Pismennaja A, Ruskule A, Doniņa S, Wex T, Malfertheiner P, Leja M, Linē A. Tumour-associated autoantibody signature for the early detection of gastric cancer. Int J Cancer. 2012 Jun 9. doi: 10.1002/ijc.27667. [[Epub ahead of print]] )(IF 4.93)\\
\\
3. Ducena K, Ābols A, Vilmanis J, Narbuts Z, Tārs J, Andrējeva D, Linē A, Pīrāgs V. Validity of multiplex biomarker model of 6 genes for the differential diagnosis of thyroid nodules. Thyroid Res. 2011 Jun 27;4(1):11. cited in Scopus 1 time. \\
\\
4. K. Silina, P. Zayakin, Z. Kalnina, L. Ivanova, I. Meistere, E. Endzelins, A. Abols, A. Stengrevics, M. Leja, K. Ducena, V. Kozirovskis, A. Linē. Sperm associated antigens as targets for cancer immunotherapy: expression pattern and humoral immune response in cancer patients. J Immunother, 2011, Jan;34(1):28-44. IF=3.593\\
\\
5. The Committee for Advanced Therapies (CAT), Schneider CK, Salmikangas P, Jilma B, Flamion B, Todorova LR, Paphitou A, Haunerova I, Maimets T, Trouvin JH, Flory E, Tsiftsoglou A, Sarkadi B, Gudmundsson K, O'Donovan M, Migliaccio G, Ancāns J, Mačiulaitis R, Robert JL, Samuel A, Ovelgönne JH, Hystad M, Fal AM, Lima BS, Moraru AS, Turčáni P, Zorec R, Ruiz S, Akerblom L, Narayanan G, Kent A, Bignami F, Dickson JG, Niederwieser D, Figuerola-Santos MA, Reischl IG, Beuneu C, Georgiev R, Vassiliou M, Pychova A, Clausen M, Methuen T, Lucas S, Schüssler-Lenz M, Kokkas V, Buzás Z, Macaleenan N, Galli MC, Linē A, Gulbinovic J, Berchem G, Frączek M, Menezes-Ferreira M, Vilceanu N, Hrubiško M, Marinko P, Timón M, Cheng W, Crosbie GA, Meade N, di Paola ML, Vandendriessche T, Ljungman P, D'Apote L, Oliver-Diaz O, Büttel I, Celis P. Challenges with advanced therapy medicinal products and how to meet them. Nat Rev Drug Discov. 2010 Mar;9(3):195-201. IF=28.712; cited in Scopus 23 times.\\
\\
6. Kalnina Z, Silina K, Bruvere R, Gabruseva N, Stengrevics A, Barnikol-Watanabe S, Leja M, Line A. Molecular characterisation and expression analysis of SEREX-defined antigen NUCB2 in gastric epithelium, gastritis and gastric cancer. Eur J Histochem, 2009, Jan-Mar; 53 (1):7-18. (cited by 2). IF=1.809; cited in Scopus 3 times.\\
\\
7. Kalniņa Z, Siliņa K and Linē A. Autoantibody profiles as biomarkers for response to therapy and early detection of cancer Current Cancer Therapy Reviews, 2008, 4 (2):149-156. cited in Scopus 4 times.\\
\\
8. Kalniņa Z, Siliņa K, Meistere I, Zayakin P, Rivosh A, Ābols A, Leja M, Minenkova O, Schadendorf D and Linē A. Evaluation of T7 and Lambda phage display systems for survey of autoantibody profiles in cancer patients. J Immunol Methods, 2008 May 20;334(1-2):37-50. IF=2.340; cited in Scopus 18 times.\\
\\
9. Li G, Assudani DP, Line A, Cao F, Miles A, Rees RC and McArdle SEB. Identification of Metastasis Associated Antigen 1 (MTA1) by Serological Screening of Prostate Cancer cDNA Libraries. Open Biochem J. 2008; 2: 100–107. \\
\\
10. Kalniņa Z, Silina K, Zajakin P and Linē A. Alterations of pre-mRNA splicing in cancer. Genes, Chromosomes & Cancer, 2005, 42,(4):342-57. IF=3.99; cited in Scopus 109 times.\\
\\
11. Li G, Miles A, Line A, Rees RC. Identification of tumour antigens by serological analysis of cDNA expression cloning. Cancer Immunol Immunother, 2004, 53 (3):139-43. IF=4.293; cited in Scopus 45 times.